Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
Sign in with Google. Opens in new tab
ENTITY
Genscript Biotech (1548 HK)
Watchlist
Contact IR
81
Analysis
Health Care
•
Hong Kong
Genscript Biotech Corp is biotech service company. The Company provides life science services and products and pre-clinical drug development services.
more
Watchlist
Contact IR
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Seven & I Holdings
•
16 Nov 2024 23:00
Last Week in Event SPACE: Seven & I, PA Gooddoctor, Nec Networks, Genscript/Legend, ASM PT, Hanwha
It’s Sunday! Pour yourself a coffee, grab a comfortable seat, and sift through a brief summary of insights on various events discussed during the...
David Blennerhassett
Follow
644 Views
Share
bullish
•
Sands China
•
13 Nov 2024 07:57
Technically Speaking, Breakouts and Breakdowns: HONG KONG (NOVEMBER 13)
Mainland China's A-share market advanced after Trump's election as South Connect buying hit a 3 year high. Sands China had a breakout as Macau...
David Mudd
Follow
303 Views
Share
bullish
•
Legend Biotech Corp
•
13 Nov 2024 00:55
Legend Biotech (LEGN.US) Offer Update - Will Deconsolidation Increase the Chances of a Merger ?
The deconsolidation of Legend Bio may not necessarily be directly related to a potential merger, but divisions among major shareholders/co-founders...
Xinyao (Criss) Wang
Follow
446 Views
Share
bearish
•
Thematic (Sector/Industry)
•
07 Nov 2024 01:02
What Does a Trump Presidency Mean for China Healthcare?
Trump successfully elected as the US President. His reform in healthcare is to achieve the independence of US pharmaceutical supply chain and...
Xinyao (Criss) Wang
Follow
508 Views
Share
bullish
•
Thematic (Sector/Industry)
•
26 Oct 2024 23:30
APAC Healthcare Weekly (Oct 27)- Samsung Biologics, Celltrion, Astellas, Otsuka, Legend, and Zai Lab
Samsung Biologics secures largest ever contract, Celltrion announced KRW100B buyback, Astellas Pharma got label expansion approval for Vyloy,...
Tina Banerjee
Follow
595 Views
Share
First
Previous
1
2
3
4
5
6
Next
Last
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.55.3
x